Group 1: Earnings Performance - Envista reported quarterly earnings of $0.24 per share, exceeding the Zacks Consensus Estimate of $0.23 per share, but down from $0.29 per share a year ago, representing an earnings surprise of 4.35% [1] - The company posted revenues of $652.9 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.09%, compared to $645.6 million in the same quarter last year [2] - Over the last four quarters, Envista has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Group 2: Stock Performance and Outlook - Envista shares have increased approximately 4.4% since the beginning of the year, outperforming the S&P 500's gain of 2.7% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $0.25 on revenues of $628.94 million, and for the current fiscal year, it is $1.13 on revenues of $2.56 billion [7] Group 3: Industry Context - The Medical - Products industry, to which Envista belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, indicating potential challenges [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Envista's stock performance [5][6]

Financial Performance - Q4 2024 net income was $1 million, a significant improvement from a net loss of $217 million in Q4 2023[5] - Adjusted EBITDA for Q4 2024 was $91 million, with an adjusted EBITDA margin of 13.9%, consistent with expectations[8] - Sales for Q4 2024 reached $653 million, reflecting a core sales increase of 2.0% compared to Q4 2023[8] - Operating cash flow for Q4 2024 was $132 million, representing a 30% increase year-over-year, while free cash flow was $124 million, up 24%[8] - The company expects core sales growth of 1% to 3% and adjusted EBITDA margins of approximately 14% for the full year 2025[9] - Adjusted earnings per share for 2025 are projected to range between $0.95 and $1.05[9] - The company reported a gross profit of $372.5 million for Q4 2024, compared to $335.9 million in Q4 2023[15] - Adjusted net income for the year ended December 31, 2024, was $126.5 million, down from $269.2 million in 2023[23] - Gross profit for the year ended December 31, 2024, was $1,372.7 million, a decrease of 4.7% from $1,440.5 million in 2023[23] - Adjusted EBITDA for the year ended December 31, 2024, was $296.1 million, down from $464.2 million in 2023[23] Cash Flow and Assets - The ending balance of cash and cash equivalents increased to $1,069.1 million in 2024 from $940.0 million in 2023[21] - Operating cash flow increased to $336.5 million in 2024 from $275.7 million in 2023, representing a 22% increase[20] - Free Cash Flow for the three months ended December 31, 2024, was $123.9 million, an increase from $99.9 million in the same period of 2023[33] - Total assets decreased to $5.35 billion as of December 31, 2024, down from $6.61 billion a year earlier[18] Segment Performance - Specialty Products & Technologies segment reported sales of $1,616.4 million for the year, down 1.6% from $1,642.4 million in 2023[25] - Equipment & Consumables segment sales decreased to $894.2 million in 2024 from $924.1 million in 2023, a decline of 3.2%[25] - Adjusted Operating Profit for the Equipment & Consumables segment for the three months ended December 31, 2024, was $60.9 million, an increase from $44.7 million in the same period of 2023, reflecting a growth of 36.2%[27] Losses and Equity - Net loss for the year ended December 31, 2024, was $1,118.6 million compared to a loss of $100.2 million in 2023[20] - The company reported an operating loss of $1,038.2 million for the year ended December 31, 2024, compared to a profit of $31.5 million in 2023[23] - The company’s total stockholders' equity was $2.93 billion as of December 31, 2024, compared to $4.17 billion at the end of 2023[18] - The company reported a net loss of $1.2 million for the three months ended December 31, 2024, compared to a net loss of $217.4 million in the same period of 2023[28] Adjusted Metrics and Non-GAAP Measures - Adjusted EBITDA is used as a supplemental measure for assessing operating performance, excluding interest, taxes, depreciation, amortization, and unusual losses or gains, to provide a clearer view of operational factors[37] - Free Cash Flow (FCF) is utilized to evaluate the company's ability to generate cash for business growth and acquisitions, although it does not account for debt service requirements[39] - Adjusted Diluted Shares Outstanding includes the dilutive impact of stock options and performance stock units, reflecting the adjusted net income compared to a net loss under GAAP[39] - The company excludes amortization of acquisition-related intangible assets from non-GAAP measures to facilitate consistent comparisons of operating results over time[39] - Core sales exclude the effects of acquisitions, divested product lines, discontinued products, and currency translation to provide a clearer view of ongoing operations[39] - Adjusted Gross Profit, Adjusted Operating Profit, and Adjusted Net Income are assessed to understand long-term profitability trends and compare performance with peers[37] - Management uses non-GAAP measures to evaluate the company's operating and financial performance, providing insights into underlying business trends[38] - The adjustments made in the financial reporting are aimed at obscuring underlying business trends and making long-term performance comparisons more challenging[39] Quarterly Performance - Adjusted Operating Profit for the three months ended December 31, 2024, was $81.5 million, compared to $89.6 million for the same period in 2023, representing a decrease of 1.1%[27] - Adjusted Net Income for the three months ended December 31, 2024, was $41.1 million, down from $49.7 million in the same period of 2023, reflecting a decline of 17.5%[28] - Adjusted Diluted Earnings Per Share for the three months ended December 31, 2024, was $0.24, compared to $0.29 for the same period in 2023, a decrease of 17.2%[29] - Total sales growth for the three months ended December 31, 2024, was 1.1%, while core sales growth was 2.0%[32] - Adjusted EBITDA for the three months ended December 31, 2024, was $91.0 million, down from $100.5 million in the same period of 2023, a decrease of 14.1%[31] - Adjusted Operating Profit as a percentage of sales for the three months ended December 31, 2024, was 12.5%, compared to 13.9% for the same period in 2023[27] - The average common stock shares outstanding - diluted for the three months ended December 31, 2024, was 173.7 million, slightly up from 173.5 million in the same period of 2023[30]

BREA, Calif., Feb. 5, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended December 31, 2024."In Q4 2024, Envista delivered results that were in line with expectations, indicating that our focus on growth, operations, and people is having a positive impact," said Paul Keel, Envista's CEO.  "2024 was a transition year for our company.  After a challenging first half, we took actions over the last two quarters to position ourselves for improved performan ...

BREA, Calif., Feb. 4, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will hold a Capital Markets Day on Wednesday, March 5, from 9:00 a.m. to 12:00 p.m. EST. This event will include a management presentation followed by a question-and-answer session. In-person attendance requires advanced registration. Those interested in attending the event in person can contact [email protected] for more information. The event and corresponding presentation will ...

Company Overview - Envista (NVST) is expected to report a year-over-year decline in earnings, with a projected EPS of $0.23, reflecting a decrease of -20.7% compared to the previous year [3] - Revenue for the upcoming quarter is anticipated to be $646.15 million, which represents a slight increase of 0.1% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 0.57% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Envista is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.22%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Historical Performance - In the last reported quarter, Envista exceeded the expected EPS of $0.09 by delivering $0.12, resulting in a surprise of +33.33% [12] - Over the past four quarters, Envista has only beaten consensus EPS estimates once [13] Market Sentiment - The upcoming earnings report is set to be released on February 5, and the stock may experience upward movement if the results exceed expectations, while a miss could lead to a decline [2] - The company's current Zacks Rank is 3, indicating a hold position, which suggests a moderate outlook for the stock [11] Industry Context - In comparison, BellRing Brands (BRBR), another player in the Zacks Medical - Products industry, is expected to post earnings of $0.47 per share, reflecting a year-over-year increase of +9.3% [17] - BellRing Brands has an Earnings ESP of 2.15% but carries a Zacks Rank of 4 (Sell), making it difficult to predict a beat on the consensus EPS estimate [18]

Earnings Announcement and Conference Call Details - Envista Holdings Corporation will report its Q4 2024 financial results on February 5, 2025, with the conference call scheduled to begin at 2:30 PM PT [1] - The conference call will last approximately one hour and will be accompanied by a slide presentation [1] - The webcast of the call and presentation will be available on the "Investors" section of Envista's website, with a replay accessible for one year [2] - Participants can access the conference call by dialing 800-225-9448 (U S) or +1 203-518-9708 (international) using conference ID 7185081 [2] - Earnings press release, webcast slides, and related materials will be posted on the "Investors" section of Envista's website before the call and remain available afterward [3] Company Overview - Envista Holdings Corporation is a global dental products company with over 30 trusted brands, including Nobel Biocare, Ormco, DEXIS, and Kerr [4] - The company focuses on partnering with dental professionals to improve patient care through dental consumables, solutions, technology, and services [4] - Envista's product portfolio includes dental implants, orthodontics, digital imaging technologies, and treatment options, addressing a wide range of clinical needs [4] - The company operates with the Envista Business System (EBS) methodology, emphasizing continuous improvement, innovation, and customer focus [4] - Envista holds significant market positions in attractive segments of the dental products industry and is one of the largest global dental products companies [4] Investor Relations Contact - James Gustafson, Vice President of Investor Relations, is the primary contact for further information regarding Envista Holdings Corporation [5] - The company's headquarters is located at 200 S Kraemer Blvd, Building E, Brea, CA 92821, with a contact number of (714) 817-7000 [5]

Group 1 - The article focuses on the Asia Value & Moat Stocks research service, which targets value investors looking for Asia-listed stocks with significant discrepancies between price and intrinsic value [1] - The service emphasizes deep value balance sheet bargains, such as net cash stocks and low price-to-book (P/B) stocks, as well as wide moat stocks that represent high-quality businesses [1] - The author provides a range of watch lists with monthly updates, particularly concentrating on investment opportunities in the Hong Kong market [1]

Earnings Announcement and Conference Call - Envista Holdings Corporation will report its Q4 2024 financial results on February 5, 2025, with a conference call scheduled for the same day at 2:00 PM PT, lasting approximately one hour [1] - The conference call and accompanying slide presentation will be webcast on the "Investors" section of Envista's website, with a replay available shortly after the conclusion and accessible for one year [2] - Participants can access the conference call by dialing 800-225-9448 within the U S or +1 203-518-9708 outside the U S, using conference ID 7185081 [2] - Envista's earnings press release, webcast slides, and related materials will be posted on the "Investors" section of the company's website before the call and remain available afterward [3] Company Overview - Envista is a global dental products company with over 30 trusted brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through partnerships with dental professionals [4] - The company offers a comprehensive portfolio of dental consumables, solutions, technology, and services, covering dental implants, orthodontics, digital imaging, and aesthetic solutions [4] - Envista operates with the Envista Business System (EBS) methodology, supported by an experienced leadership team and a culture of continuous improvement, innovation, and customer focus [4] - As one of the largest global dental products companies, Envista holds significant market positions in attractive segments of the dental industry [4]

Company Overview - Envista Holdings Corporation is a global leader in the dental products industry, with a portfolio of over 30 trusted dental brands including Nobel Biocare, Ormco, DEXIS, and Kerr [2] - The company focuses on partnering with dental professionals to improve patient care through innovative dental consumables, solutions, technology, and services [2] - Envista's comprehensive product portfolio includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for diagnosing, treating, and preventing dental conditions [2] - The company operates with the Envista Business System (EBS) methodology, emphasizing continuous improvement, innovation, and customer focus [2] - Envista holds significant market positions in some of the most attractive segments of the dental products industry [2] Upcoming Event - Envista will participate in a presentation at the 43rd Annual J P Morgan Healthcare Conference on January 15, 2025, from 9:45 – 10:25 am PT at the Westin St Francis Hotel in San Francisco [1] - An audio-only recording of the presentation will be available on Envista's Investor Relations website for up to 30 days following the event [1]

Envista Holdings Corporation’s (NVST) rise in the third quarter of 2024 is backed by robust growth within the Specialty Products and Technologies business. Strategic acquisition deals look promising for growth. Meanwhile, a debt-burdened balance sheet and dull macroeconomic environment remain concerns for NVST’s operations.  In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 8.8% against 17.3% growth of the industry. The S&P 500 composite rose 30.8% during the same time frame.The leading ...